Santhera Pharmaceuticals Holding AG Share Price OTC Markets

Equities

SPHDF

CH1276028821

Pharmaceuticals

Market Closed - OTC Markets 17:23:09 22/02/2024 GMT 5-day change 1st Jan Change
11.7 USD +4.00% Intraday chart for Santhera Pharmaceuticals Holding AG -.--% -.--%

Financials

Sales 2024 * 24M 26.78M 2.09B Sales 2025 * 60M 66.95M 5.23B Capitalization 76.39M 85.24M 6.66B
Net income 2024 * -35M -39.05M -3.05B Net income 2025 * -10M -11.16M -872M EV / Sales 2024 * 3.18 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.27 x
P/E ratio 2024 *
-2.95 x
P/E ratio 2025 *
-11.1 x
Employees 45
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Santhera Pharmaceuticals Holding AG - Special Call
Santhera Secures CHF69 Million Financing for Bond Repayment, Cash Runway Extension MT
Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows MT
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis MT
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China MT
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA CI
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment MT
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy CI
Swiss Equities Get a Boost from UK’s Upside GDP Surprise MT
Santhera Pharmaceuticals Obtains UK Approval for Duchenne Muscular Dystrophy Treatment MT
Swiss Equities Edge Down After Central Banks Buzz MT
More news

Latest transcript on Santhera Pharmaceuticals Holding AG

Current year
11.25
Extreme 11.25
11.70
1 year
9.40
Extreme 9.4
13.35
3 years
6.80
Extreme 6.8
28.10
5 years
6.80
Extreme 6.8
142.50
10 years
6.80
Extreme 6.8
1 371.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 30/11/19
Founder 62 06/09/04
Director of Finance/CFO 61 31/03/20
Members of the board TitleAgeSince
Founder 62 06/09/04
Director/Board Member 56 03/04/17
Director/Board Member 68 26/06/23
More insiders
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.29 CHF
Average target price
34.5 CHF
Spread / Average Target
+316.16%
Consensus

Quarterly revenue - Rate of surprise